GEXVal Selected as Presenting Company at Biotech Showcase™ 2026

株式会社GEXVal
January 7, 2026

GEXVal Selected as Presenting Company at Biotech Showcase™ 2026

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce its selection as a presenting company at Biotech Showcase™ 2026, co-hosted by Demy-Colton and EBD Group. This prestigious business conference is one of the world's leading platforms for strategic partnerships, licensing opportunities, and capital formation in the global biotechnology and pharmaceutical industries.

Juran Kato, PhD, President and CEO of GEXVal, stated: "We are deeply honored to have been selected as a presenting company at Biotech Showcase™ 2026. This event brings together companies, researchers, and investors who share our vision of developing innovative therapies that can transform patient care. We look forward to engaging in meaningful dialogue with stakeholders about our drug development programs targeting unmet medical needs in Fragile X syndrome, neurodevelopmental disorders, and cognitive impairments. We will do our utmost to advance collaborative opportunities that contribute to the future of medicine."

[Event Overview]
Biotech Showcase™ is an international business forum where innovative biopharma companies present their R&D achievements and business strategies in cutting-edge fields including drug discovery and diagnostic technologies. The event brings together startups, pharmaceutical companies, investors, and research institutions to facilitate strategic partnerships, licensing opportunities, and capital formation.

**Event Details**

[About Fragile X Syndrome]
Fragile X syndrome (FXS) is a rare genetic disorder caused by mutations in the FMR1 gene, resulting in loss of FMRP protein function. FXS is estimated to occur in approximately 1 in 2,400 to 6,000 births. While diagnosis is more common in Western countries, FXS remains largely underdiagnosed in Japan despite similar prevalence rates. Currently, there are no approved disease-modifying treatments for FXS.

Characteristics: FXS is a complex syndrome presenting with diverse symptoms. It is classified within autism spectrum disorders (ASD) and typically includes autistic-like behaviors, attention difficulties and hyperactivity, anxiety, sensory sensitivities, epilepsy, sleep disturbances, and learning difficulties. According to the FRAXA Research Foundation, FXS is the most common inherited cause of autism and cognitive challenges.

Additional Resources:
National Organization for Rare Disorders (NORD): https://rarediseases.org/rare-diseases/fragile-x-syndrome/
Orphanet: https://www.orpha.net/en/disease/detail/908
FRAXA Research Foundation: https://www.fraxa.org

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有关本事宜请咨询:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com